Monday, May 28

08:30-11:30

Symposium II

New Concepts in Understanding Ovarian Cancer Initiation and Progression

Selected Oral Presentations from Scientific Abstracts

OC-02.01
DACHSHUND HOMOLOG 2 REGULATES CELL FATE IN THE FALLOPIAN TUBE DURING THE MENSTRUAL CYCLE
Rania Chehade ; Sophia George ; Jennifer Cruikshank ; Noor Salman ; Bernard Martin ; Jason Moffat ; Troy Ketela ; Patricia Shaw ; Mona Gauthier ; Hal Berman
University of Toronto, Toronto, ON, Canada

OC-02.02
THE LOSS OF HOXA5 FUNCTION CAUSES ESTROUS ACYCLICITY AND OVARIAN EPITHELIAL INCLUSION CYSTS
Lucie Jeannotte ; Gaëlle Gendronneau ; Olivier Boucherat
Centre de recherche en cancérologie de l'Université Laval, Quebec, QC, Canada

OC-02.03
ASSESSING THE EVOLUTION AND IMMUNOGENICITY OF THE OVARIAN CANCER GENOME
Brad Nelson ¹; Mauro Castellarin ²; John Webb 3; Darin Wick ³; Peter Watson ³; Rob Holt ^2
1Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada; ²Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada; ³Deeley Research Centre, BC Cancer Agency, Victoria, BC, Canada

OC-02.04
NOTCH3 ACTIVATION UP-REGULATES GUCY1B3 EXPRESSION IN OVARIAN CANCER AND IMMORTALIZED OVARIAN SURFACE EPITHELIAL CELLS
YangXin Fu Fu ; Nidhi Gupta ; Ahmed El-Sehemy ; Zhihua Xu ; Helen Steed
University of Alberta, Edmonton, AB, Canada

OC-02.05
HUMAN EPIDIDYMIS PROTEIN 4 (HE4) AND OVARIAN CANCER PROGNOSIS
Dominique Trudel ¹; Isabelle Bairati ²; Bernard Têtu ³; Jean Grégoire ⁴; Marie Plante ⁴; Marie-Claude Renaud ⁴; Dimcho Bachvarov ³; Pierre Douville ^3
1Toronto General Hospital, University Health Network, Toronto, ON, Canada; ²Clinical Epidemiology Unit, Laval University Cancer Research Center, CHUQ-L’Hôtel-Dieu, Quebec, QC, Canada; ³Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Laval University, Quebec, QC, Canada; ⁴Department of Gyneco-oncology, L’Hôtel-Dieu de Québec from the Centre Hospitalier Universitaire de Québec, Quebec, QC, Canada

11:30-13:30

Lunch and Poster Session II

12:00-13:30

P.02
ORGANIZING CELLULAR AND MOLECULAR HETEROGENEITY IN HIGH-GRADE SEROUS OVARIAN CANCER
Jocelyn Stewart ¹; Bernd Bodenmiller ²; Laurie Ailles ³; Marcus Bernardini ³; Patricia Shaw ³; Garry Nolan ⁴; Benjamin Neel ^3
1University of Toronto/Ontario Cancer Institute, Toronto, ON, Canada; ²ETH Zurich, Zurich, Switzerland; ³Ontario Cancer Institute, Toronto, ON, Canada; ⁴Stanford University, Palo Alto, CA, United States

P.05
INTERACTION OF MUC16 (CA125) WITH β-CATENIN
Panagiota Giannakouros ; Isabelle Matte ; Claudine Rancourt ; Alain Piché
Departement de Microbiologie et Infectiologie, FMSS, Université de Sherbrooke, Sherbrooke, QC, Canada

P.08
HYPERGLYCEMIA ACCELERATES THE PROGRESSION OF EPITHELIAL OVARIAN CANCER IN MICE, WHICH MAY BE MEDIATED BY ACTIVE SODIUM-GLUCOSE CO-TRANSPORT
Lisa Kellenberger ¹; Alison Holloway ²; Jim Petrik ^1
1University of Guelph, Guelph, ON, Canada; ²McMaster University, Hamilton, ON, Canada

P.11
CONTRIBUTION OF RECURRENT BRCA1 MUTATIONS TO OVARIAN CANCER CASES IN THE FRENCH CANADIAN POPULATION OF QUEBEC
Lena Dolman ¹; Moria H. Belanger ¹; Suzanna L. Arcand ²; Zhen Shen ³; George Chong ³; Anne-Marie Mes-Masson ⁴; Diane Provencher ⁵; Patricia N. Tonin ^6
1Department of Human Genetics, McGill University; ²The Research Institute of the McGill University Health Centre; ³Molecular Pathology Unit, Department of Pathology, Jewish General Hospital, McGill University; ⁴Département de médecine, Université de Montréal; ⁵Division de gynécologie oncologique, Université de Montréal; ⁶Departments of Medicine and Human Genetics, McGill University; The Research Institute of the McGill University Health Centre; Montreal, QC, Canada

P.14
THE CONTRIBUTION OF RECURRENT BRCA2 MUTATIONS AMONG FRENCH CANADIAN OVARIAN CANCER CASES
Moria H. Belanger ¹; Lena Dolman ¹; Suzanna L. Arcand ²; Zhen Shen ³; George Chong ³; Anne-Marie Mes-Masson ⁴; Diane Provencher ⁵; Patricia N. Tonin ^6
1Department of Human Genetics, McGill University; ²The Research Institute of the McGill University Health Centre; ³Molecular Pathology Unit, Department of Pathology, Jewish General Hospital, McGill University; ⁴Département de médecine, Université de Montréal; Centre de recherche du Centre Hospitalier de l'Université de Montréal,; ⁵Division de gynécologie oncologique Université de Montréal ; Centre de recherche du Centre Hospitalier de l'Université de Montréal; ⁶Departments of Medicine and Human Genetics, McGill University; The Research Institute of the McGill University Health Centre; Montreal, QC, Canada

P.17
ENDOMETRIOSIS IS AN OVARIAN PRECURSOR LESION: THE MUTATIONAL BASIS OF ITS TRANSFORMATION
Alicia Tone ¹; Michelle Woo ²; Ali Bashashati ²; Paul Yong ³; Catherine Allaire ³; Christina Williams ³; Sohrab Shah ²; Blake Gilks ¹; David Huntsman ^2
1University of British Columbia; ²BC Cancer Agency; ³BC Women's Hospital; Vancouver, BC, Canada

P.20
CHRONIC LOW-GRADE, SYSTEMIC INFLAMMATION ACCELERATES THE PROGRESSION OF EPITHELIAL OVARIAN CANCER (EOC) IN VIVO
Amanda Kerr ; Lisa Kellenberger ; Jim Petrik
University of Guelph, Guelph, ON, Canada

P.23
INTERACTIONS BETWEEN BRCA1 AND THE IGF-1R SIGNALING PATHWAY IN HUMAN EPITHELIAL OVARIAN CANCER CELLS
Marie-Claude Beauchamp ; Amber Yasmeen ; Sanaa Iqbal ; Laura Drudi ; Walter H. Gotlieb
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada

P.26
IMPACT OF RAN GTPASE IN OVARIAN CANCER PROGRESSION
Katia Y. Caceres G. ¹; V. Barres ²; E. Carmona ³; P. Tonin ⁴; D. Provencher ⁵; A-M. Mes-Masson ^6
1Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; ²Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; ³Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; ⁴The Research Institute of the McGill University Health Center; Department of Medicine; Department of Human Genetics; ⁵Division of Gynecologic Oncology, Université de Montréal; Institut du cancer de Montréal, CRCHUM; ⁶Institut du Cancer de Montréal, CRCHUM; Département de médecine, Université de Montréal; Montreal, QC, Canada

P.29
GERMLINE TP53 MUTATIONS IN BREAST/OVARIAN CANCER FAMILIES OF FRENCH CANADIAN DESCENT
Suzanna Arcand ¹; Laura Palma ²; Nora Wong ³; Lidia Kasprzak ²; Anne-Marie Mes-Masson ⁴; Parviz Ghadirian ⁵; William Foulkes ⁶; Diane Provencher ⁷; Patricia Tonin ^8
1The Research Institute of the McGill University Health Centre; ²Department of Medical Genetics, McGill University Health Centre; ³Department of Medical Genetics, Cancer Prevention Centre, Jewish General Hospital; ⁴Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; ⁵Epidemiology Research Unit, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM); ⁶Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University; ⁷Division of Gynecologic Oncology, Université de Montréal; ⁸The Research Institute of the McGill University Health Centre; Departments of Medicine and Human Genetics, McGill University; Montreal, QC, Canada

P.32
CHARACTERIZATION OF THE RUNX1 AND RUNX2 AS HYPOMETHYLATED GENES IN ADVANCED OVARIAN CANCER: POSSIBLE ROLES IN OVARIAN CANCER PROGRESSION, INVASION/METASTASIS AND CHEMORESISTANCE
Mamadou Keita ¹; Dimcho Bachvarov ¹; Eric Paquet ²; Magdalena Bachvarova ²; Marie Plante ³; Jean Gregoire ³; Marie-Claude Renaud ³; Chantale Morin ⁴; Anne-Marie Mes-Masson ^5
1Department of Molecular Medicine, Laval University, Quebec, QC, Canada; ²Cancer Research Centre, Hôpital L’Hôtel-Dieu de Québec, Centre Hospitalier Universitaire de Québec (CHUQ), Quebec, QC, Canada; ³Department of Obstetrics and Gynecology, Laval University, Quebec, QC, Canada; ⁴Department of Pathology, Laval University, Quebec, QC, Canada; ⁵Department of Medicine, University of Montreal, Montreal, QC, Canada

P.35
EXPLORATORY IMMUNOHISTOCHEMICAL INVESTIGATION OF ANAEROBIC GLYCOLYSIS AND ALTERED TUMOR METABOLISM IN OVARIAN CANCER
Jason Madore ¹; Steve Kalloger ²; Julie Lorette ³; Samuel Aparicio ⁴; David Huntsman ^5
1Pathology and Lab Medicine, UBC; ²GPEC, Pathology VGH, UBC; ³CTAG, BCCA; ⁴Molecular Oncology BCCA-CRC, UBC; ⁵CTAG, BCCA, Pathology and Lab Medicine, UBC; Vancouver, BC, Canada

P.38
CHARACTERIZATION OF BOVINE OVIDUCTAL EPITHELIAL CELLS IN CULTURE AND INFLAMMATORY RESPONSE TO FOLLICULAR FLUID EXPOSURE
Angela Lau ¹; Alexandra Kollara ¹; Elizabeth St. John ²; Alicia Tone ³; Ellen M. Greenblatt ⁴; W. Allan King ²; Theodore J. Brown ^2
1Mount Sinai Hospital Samuel Lunenfeld Research Institute, Toronto, ON, Canada; ²Department of Bioscience, University of Guelph Veterinary School, Guelph, ON, Canada; ³Department of Obstetrics and Gynaecology, Toronto, ON, Canada; ⁴Mount Sinai Hospital Department of Obstetrics and Gynaecology, Toronto, ON, Canada

P.44
ANDROGEN RECEPTOR EXPRESSION IN EPITHELIAL STRUCTURES OF THE OVARY IN PERIMENOPAUSE
Maria Del Carmen Mendez ¹; Flavia Morales Vasquez ²; Delia Perez-Montiel ²; Veronica Diaz-Hernandez ¹; Martin Cadena-Sandoval ¹; Maria Jose Gomora ¹; Gonzalo Montalvo ²; Enrique Perdernera ^1
1Universidad Nacional Autonoma De Mexico, Mexico; ²Instituto Nacional De Cancerologia, Mexico

P.47
TGFβ/BMP SIGNALLING REGULATION OF THE EMT PHENOTYPE IN ASCITES-DERIVED EPITHELIAL OVARIAN CANCER SPHEROIDS
Samah Rafehi ; Teresa Peart ; Yudith Valdes ; Gabriel DiMattia ; Trevor Shepherd
The University of Western Ontario, London, ON, Canada

P.50
LOSS OF LKB1 IS AN EARLY EVENT IN HIGH-GRADE SEROUS CARCINOMA
Sophia H.L. George ¹; Anca Milea ¹; Mona Gauthier ¹; Patricia Shaw ^2
1Campbell Family Institute for Breast Cancer Research; ²Campbell Family Institute for Breast Cancer Research/ University Health Network; Toronto, ON, Canada

P.53
GLUCOCORTICOID-INDUCED REVERSAL OF INTERLEUKIN-1β (IL-1β)-STIMULATED INFLAMMATORY GENE EXPRESSION IN FALLOPIAN TUBE EPITHELIAL CELLS
Stephanie Backman ¹; Alexandra Kollara ¹; Carl Virtanen ²; Theodore Brown ^1
1University of Toronto; ²OCI Microarray Center; Toronto, ON, Canada

P.55
NODAL ENHANCES MIGRATION AND INVASIVENESS OF EPITHELIAL OVARIAN CANCER CELLS
Christine Zhang (equal contribution) ¹; YaoYun Liang (equal contribution) ¹; Jakie Feng ¹; Zhaogun Deng ²; Burton Yang ²; Chun Peng ^1
1Department of Biology, York University; ²Sunnybrook Research Institute, Sunnybrook Health Sciences Centre; Toronto, ON, Canada

P.56
REPORT ON A QUALITY CONTROL EXERCISE PERFORMED ON SPECIMENS FROM CANADIAN BIOBANKS PARTICIPATING IN THE COEUR SPECIMEN REPOSITORY
Manon de Ladurantaye ¹; Cécile Le Page ¹; Martin Kobel ²; Kurosh Rahimi ³; Jason Madore ¹; Sindy Babinszky ⁴; Dimcho Bachvarov ⁵; Magdalena Bachvarova ⁶; Marie-Claude Beauchamp ⁷; Carol E. Cass ⁸; Dianne Chadwick ⁹; Colleen Crane ¹⁰; Sambasivarao Damaraju ⁸; Jennifer Dufour ⁸; Walter H. Gotlieb ⁷; Steve E. Kalloger ¹¹; Lise Portelance ¹; Jessica N. McAlpine ¹²; Isabelle Matte ¹³; Alain Piché ¹³; Patricia Shaw ⁹; Barbara C. Vanderhyden ¹⁰; Peter H. Watson ⁴; David G. Huntsman ¹¹; Diane M. Provencher ¹; Anne-Marie Mes-Masson ^1
1ICM/CR-CHUM, Montreal, Qc, Canada; ²Foothills Medical Center, Calgary, AB, Canada; ³Hopital Notre-Dame / CHUM, Montreal, QC, Canada; ⁴BC Cancer Agency, Victoria, BC, Canada; ⁵Université de Laval, Montreal, QC, Canada; ⁶CRCCHUQ, Montreal, QC, Canada; ⁷Segal Cancer Center, Montreal, QC, Canada; ⁸Cross Cancer Institute, Edmonton, AB, Canada; ⁹PMH/UHN, Toronto, ON, Canada; ¹⁰Ottawa Research Hospital Institute, Ottawa, ON, Canada; ¹¹Vancouver General Hospital, Vancouver, BC, Canada; ¹²University of BC, Vancouver, BC, Canada; ¹³Université de Sherbrooke, Sherbrooke, QC, Canada

13:30-18:00

Symposium III

Targeted Therapies and Current and Emergent Clinical Trials

Special Lecture

15:50-18:15

Selected Oral Presentations from Scientific Abstracts

OC-03.01
THROMBOSPONDIN-1 TREATMENT INDUCES REGRESSION OF ADVANCED STAGE EPITHELIAL OVARIAN CANCER AND SIGNIFICANTLY INCREASES DISEASE FREE SURVIVAL
Nicolle Linnerth-Petrik ¹; James Greenaway ¹; Jack Lawler ²; Jim Petrik ^1
1University of Guelph, Guelph, ON, Canada; ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

OC-03.02
A SMALL MOLECULE KINASE INHIBITOR SCREEN TO IDENTIFY NOVEL TREATMENTS FOR CLEAR CELL CARCINOMA
Kimberly Wiegand ¹; Arthur V. Sampaio ²; Steve Kalloger ²; Alicia Tone ¹; T. Michael Underhill ²; David G. Huntsman ^1
1BCCA and The University of British Columbia; ²The University of British Columbia; Vancouver, BC, Canada

OC-03.03
PATHWAYS ASSOCIATED WITH DIFFERENTIAL ACCUMULATION OF ASCITES IN HIGH GRADE SEROUS OVARIAN CANCER: A SEARCH FOR TARGETED THERAPY TO CONTROL ASCITES
Tomer Feigenberg ¹; Carl Virtanen ²; Michelle Letarte ³; Marcus Bernardini ⁴; Blaise Clarke ⁵; Theodore Brown ⁶; Barry Rosen ⁷; K. Joan Murphy ^7
1University of Toronto; ²UHN Microarray Centre; ³Hospital for Sick Children and Department of Immunology, University of Toronto; ⁴Department of Obstetrics and Gynecology, Division of Gyn-Oncology University Health Network (UHN); ⁵Department of Pathology, University Health Network (UHN); ⁶Department of Obstetrics and Gynecology, University Health Network (UHN) and Mt. Sinai Hospital; ⁷Department of Obstetrics and Gynecology, Division of Gyn-Oncology University Health Network (UHN); Toronto, ON, Canada

OC-03.04
PARP INHIBITORS IN THE TREATEMENT OF OVARIAN CANCER
Hubert Fleury ¹; Euridice Carmona ¹; Diane Provencher ¹; Elliot Drobetsky ²; Anne-Marie Mes-Masson ^1
1CRCHUM / ICM; ²Centre de recherche de l’Hôpital Rosemont; Montreal, QC, Canada

OC-03.05
ASCITES-DERIVED PRIMARY CANCER CELL CULTURES AS A MODEL TO TEST TARGETED THERAPIES IN PATIENTS WITH ADVANCED OVARIAN CANCER
Xuan Bich Trinh ¹; Magdalena Bachvarova ¹; Jean- François Pelletier ¹; Jean Grégoire ²; Marie-Claude Renaud ²; Alexandra Sebastianelli ²; Marie Plante ²; Dimcho Bachvarov ^3
1Cancer Research Centre, Hôpital L’Hôtel-Dieu de Québec, Centre Hospitalier Universitaire de Québec; ²Gynecological Oncology Division, Hôpital L'Hôtel Dieu de Québec; ³Department of Molecular Medicine, Laval University; Quebec, QC, Canada

OC-03.06
DECREASED SEVERITY OF OVARIAN CANCER IN HENS FED FLAXSEED: ANTI-INFLAMMATORY ACTIONS TARGET E-CADHERIN (CDH1), MIR200A AND ZEB1
Karen Hales ; Sheree Speckman ; Buck Hales
Southern Illinois University School of Medicine, Carbondale, IL, United States

OC-03.07
COMBINED INHIBITION OF AKT ACTIVITY AND AUTOPHAGY SYNERGISTICALLY REDUCES EPITHELIAL OVARIAN CANCER SPHEROID CELL SURVIVAL
Rohann Correa ; Gabriel DiMattia ; Trevor Shepherd
The University of Western Ontario, London, ON, Canada

OC-03.08
PHARMACOLOGICAL TARGETING OF MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITS OVARIAN GRANULOSA CELL TUMOR GROWTH
Charlène Rico ¹; Marie-Noëlle Laguë ¹; Mayra Tsoi ¹; Aurore Dodelet-Devillers ¹; Vikas Kumar ¹; Marilène Paquet ²; Marie-Eve Nadeau ¹; Derek Boerboom ^1
1Faculté de Biomédecine Vétérinaire, Saint-Hyacinthe, QC, Canada; ²Université McGill, Montreal, QC, Canada

OC-03.09
CHARACTERIZATION OF MUCINOUS OVARIAN TUMORS: ASSESSING THE PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF HER2 AMPLIFICATION AND OTHER BIOMARKERS AS A STEP TOWARDS MOLECULAR TARGETED THERAPY
Jessica N. McAlpine ¹; Henry Porter ²; MC Tolcher ³; Blaise Clarke ⁴; Michael S. Anglesio ⁵; Sambasivarao Damaraju ⁶; Jamie Bakkum-Gamez ³; Steve E. Kalloger ²; David Bowtell ⁷; David G. Huntsman ⁵; C. Blake Gilks ^2
1University of British Columbia, Vancouver, BC, Canada; ²University of British Columbia, Vancouver, BC, Canada; ³Mayo Clinic, Rochester, MN, United States; ⁴University of Toronto, Toronto, ON, Canada; ⁵Centre for Translational and Applied Genomics, Vancouver, BC, Canada; ⁶University of Alberta, Edmonton, AB, Canada; ⁷Peter MacCallum Cancer Center, Melbourne, Victoria, Australia

18:15-18:30

Discussion Forum: Unified Criteria for Tissue and Data Banking